ENSC vs PCRX

For growth investors, Ensysce Biosciences, Inc.

(ENSC) is the stronger pick with 133. 5% revenue growth year-over-year, versus 3. 6% for Pacira BioSciences, Inc. (PCRX). Pacira BioSciences, Inc. (PCRX) offers the better valuation at 147. 8x trailing P/E (8. 6x forward), making it the more compelling value choice. Analysts rate Pacira BioSciences, Inc. (PCRX) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Pacira BioSciences, Inc.

(PCRX) delivered a total return of -62. 6%, compared to -100. 0% for Ensysce Biosciences, Inc. (ENSC). Over 10 years, the gap is even starker: PCRX returned -51. 2% versus ENSC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.

(PCRX) is the lower-risk stock at 0. 47β versus Ensysce Biosciences, Inc. 's 1. 02β — meaning ENSC is approximately 118% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Ensysce Biosciences, Inc. (ENSC) carries a lower debt/equity ratio of 9% versus 66% for Pacira BioSciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ensysce Biosciences, Inc.

(ENSC) is pulling ahead at 133. 5% versus 3. 6% for Pacira BioSciences, Inc. (PCRX). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to 2. 6% for Ensysce Biosciences, Inc.. Over a 3-year CAGR, ENSC leads at 13. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pacira BioSciences, Inc.

(PCRX) is the more profitable company, earning 1. 0% net margin versus -153. 3% for Ensysce Biosciences, Inc. — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PCRX leads at 4. 6% versus -129. 2% for ENSC. At the gross margin level — before operating expenses — PCRX leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ENSC (100.

0% yield) pays a dividend. PCRX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pacira BioSciences, Inc.

(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (PCRX: -51. 2%, ENSC: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ENSC is a small-cap high-growth stock; PCRX is a small-cap quality compounder stock. ENSC pays a dividend while PCRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.